MedPath

湖北多瑞药业有限公司

Ownership
-
Established
2005-08-22
Employees
-
Market Cap
-
Website
http://www.hbdryy.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

26

NMPA:26

Drug Approvals

Ceftizoxime Sodium for Injection

Product Name
注射用头孢唑肟钠
Approval Number
国药准字H20254471
Approval Date
Jun 10, 2025
NMPA

Compound Sodium Acetate Ringer's Injection

Product Name
复方醋酸钠林格注射液
Approval Number
国药准字H20253873
Approval Date
Apr 15, 2025
NMPA

Compound Sodium Acetate Ringer's Injection

Product Name
复方醋酸钠林格注射液
Approval Number
国药准字H20253874
Approval Date
Apr 15, 2025
NMPA

Glucose and Sodium Chloride Injection

Product Name
葡萄糖氯化钠注射液
Approval Number
国药准字H20094145
Approval Date
Oct 17, 2024
NMPA

Compound Sodium Chloride Injection

Product Name
复方氯化钠注射液
Approval Number
国药准字H20094137
Approval Date
Oct 17, 2024
NMPA

Glucose Injection

Product Name
葡萄糖注射液
Approval Number
国药准字H20094148
Approval Date
Oct 17, 2024
NMPA

Glucose Injection

Product Name
葡萄糖注射液
Approval Number
国药准字H20094099
Approval Date
Oct 17, 2024
NMPA

Glucose Injection

Product Name
葡萄糖注射液
Approval Number
国药准字H20094146
Approval Date
Oct 17, 2024
NMPA

Glucose Injection

Product Name
葡萄糖注射液
Approval Number
国药准字H20094100
Approval Date
Oct 17, 2024
NMPA

Glucose Injection

Product Name
葡萄糖注射液
Approval Number
国药准字H20094098
Approval Date
Oct 17, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.